Form 4: Madrigal Pharmaceuticals Director Richard S. Levy Executes Stock Option and Sells Shares

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard S. Levy, a director of Madrigal Pharmaceuticals, executed a transaction involving the company's stock on November 7, 2024.
• Levy exercised stock options to acquire 5,000 shares of common stock at a price of $7.36 per share.
• Simultaneously, Levy sold 5,000 shares of common stock at $350 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 30, 2023.
• Following these transactions, Levy directly owns 11,012 shares of Madrigal Pharmaceuticals common stock.
• Levy also directly owns options to purchase 5,000 shares of common stock at an exercise price of $7.36, which are fully vested and exercisable.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan suggests that the transactions were pre-planned and not based on any material non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates